# Safety and Effectiveness of Regorafenib

> **NCT02042144** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1034 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Stivarga (Regorafenib, BAY73-4506)

## Key facts

- **NCT ID:** NCT02042144
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-08
- **Primary completion:** 2017-08-19
- **Final completion:** 2017-11-10
- **Target enrollment:** 1034 (ACTUAL)
- **Last updated:** 2018-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042144, "Safety and Effectiveness of Regorafenib". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02042144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*